Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study

Liver International

Volumn 35, Issue 2, 2015, Pages 482-488

  Mottola, Leonardo ^a   Cenderello, Giovanni ^b   Piazzolla, Valeria A ^a   Forte, Paolo ^c   Carretta, Vito ^d   Mecenate, Fabrizio ^e   Brancaccio, Giuseppina ^f   Minisini, Rosalba ^g   Zuin, Massimo ^h   Terreni, Natalia ⁱ   Monti, Monica ^j   Colombo, Alberto Eraldo ^k   Nosotti, Lorenzo ^l   Minerva, Nicola ^m   Luzzitelli, Ilaria ⁿ   Kostandini, Alba ^o   Cuccorese, Giuseppe ^p   Russello, Maurizio ^q   Santoro, Rosanna ^a   Mangia, Alessandra ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Hospital Venosa   (Italy)

^e Villa Betania Hospital   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h SAN PAOLO HOSPITAL   (Italy)

ⁱ VALDUCE HOSPITAL   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k SANT ANNA HOSPITAL   (Italy)

^l ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^m Hospital Canosa   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^p Department of Gastroenterology 'Raffaele Dimiccoli' Hospital   (Italy)

^q GARIBALDI HOSPITAL   (Italy)

more..

Author keywords

Genotype 1; Hepatitis C; Interleukin 28B; Naive; Related gene polymorphisms

Indexed keywords

INTERLEUKIN 28B; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CHRONIC PATIENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; POPULATION; PREVALENCE; PROSPECTIVE STUDY; VIRAL CLEARANCE; CLINICAL TRIAL; ELASTOGRAPHY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; GENOTYPE; ITALY; NONPARAMETRIC TEST; PATHOLOGY; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ELASTICITY IMAGING TECHNIQUES; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HEPATITIS C; HUMANS; INTERLEUKINS; ITALY; LINKAGE DISEQUILIBRIUM; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; STATISTICS, NONPARAMETRIC;

EID: 84921469628     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12630     Document Type: Article

References (30)

1. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
2. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-01.
3. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
4. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
5. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
6. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
7. di Iulio J, Ciuffi A, Fitzmaurice K, et al. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011; 53: 1446-54.
8. Petta S, Grimaudo S, Cammà C, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 56: 1356-62.
9. Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-72.
10. Di Marco V, Covolo L, Calvaruso V, et al. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis J Viral Hepat 2013; 20: 790-800.
11. Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011; 54: 772-80.
12. Andriulli A, Di Marco V, Margaglione M, et al. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014; 60: 16-21.
13. Bitetto D, Bortolotti N, Falleti E, et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 2013; 57: 925-33.
14. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7.
15. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
16. Eslam M, Leung R, Romero-Gomez M, et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 2014 Apr 24; DOI: 10.1016/j.jhep.2014.03.039.
17. Montes-Cano MA, García-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-7.
18. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
19. Mangia A, Gentile R, Cascavilla I, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30: 984-9.
20. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis 2002; 6: 335-47.
21. Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology 2010; 139: 1794-6.
22. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
23. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
24. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-50.
25. Duggal P, Thio CL, Wojcik GL, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013; 158: 235-45.
26. Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
27. Lindh M, Lagging M, Norkrans G, Hellstrand K. Observed and calculated interleukin-28B genotype frequencies in hepatitis C virus infection. Hepatology 2010; 52: 1860-1.
28. Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384-94.
29. Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127-34.
30. Ydreborg M, Westin J, Rembeck K, et al. Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS ONE 2013; 8: e80172.